BIOTECH 4BM3 Lecture Notes - Lecture 7: Biopharmaceutical, Post-Translational Modification, Periplasm
12 Feb 2018
School
Department
Course
Professor
Document Summary
Vast majority of biopharms on the marker are produced by genetic engineering (proteins) Most of these products so far are made using either recombinant e. coli or mammalian cell lines. This is done by incorporating a gene or cdna coding for the proteins of interest. Expression of protein in cells in which they do not naturally occur. Advantages that lead e. coli to be the primary source of biopharmaceuticals. High levels of expression of heterologous proteins is possible (up to 30% tcp total cellular protein) Ptms are important for the protein to be folded properly. Could lead to the increase in the half-life. Presence of lipopolysaccharide (lps) endotoxins on its surface. Low solubility of mammalian proteins in prokaryotic cells. Few are exported to the periplasmic space or are released as true extracellular proteins. This created an additional problem: additional steps are needed, cellular homogenization with subsequent removal of cell debris by centrifugation or filtration.
